These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study. Pavel M; Lahner H; Hörsch D; Rinke A; Denecke T; Koch A; Regnault B; Helbig D; Hoffmanns P; Raderer M Oncologist; 2024 May; 29(5):e643-e654. PubMed ID: 38206830 [TBL] [Abstract][Full Text] [Related]
3. Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine tumors? Völter V; Peschel C J Clin Oncol; 2004 Feb; 22(3):573; author reply 574-5. PubMed ID: 14752089 [No Abstract] [Full Text] [Related]
4. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors. Fazio N; Oberg K J Clin Oncol; 2004 Feb; 22(3):573-4; author reply 574-5. PubMed ID: 14752088 [No Abstract] [Full Text] [Related]
5. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B; J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945 [TBL] [Abstract][Full Text] [Related]
6. Regression of metastatic vipoma with somatostatin analogue SMS 201-995. Clements D; Elias E Lancet; 1985 Apr; 1(8433):874-5. PubMed ID: 2858733 [No Abstract] [Full Text] [Related]
8. Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors. Squires MH; Worth PJ; Konda B; Shah MH; Dillhoff ME; Abdel-Misih S; Norton JA; Visser BC; Dua M; Pawlik TM; Schmidt CR; Poultsides G; Cloyd JM Pancreas; 2020 Mar; 49(3):355-360. PubMed ID: 32132509 [TBL] [Abstract][Full Text] [Related]
9. Metastatic jejunal VIPoma: beneficial effect of combination therapy with interferon-alpha and 5-fluorouracil. Cellier C; Yaghi C; Cuillerier E; Siauve N; Berger A; Carnot F; Haddad C; Barbier JP; Landi B Am J Gastroenterol; 2000 Jan; 95(1):289-93. PubMed ID: 10638600 [TBL] [Abstract][Full Text] [Related]
10. [Long-term therapy of a metastasizing pancreatic vipoma using the somatostatin derivative octreotide]. Flückiger A; Schlup P Schweiz Med Wochenschr; 1992 Aug; 122(33):1221-3. PubMed ID: 1326786 [TBL] [Abstract][Full Text] [Related]
12. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594 [TBL] [Abstract][Full Text] [Related]
13. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Fjällskog ML; Sundin A; Westlin JE; Oberg K; Janson ET; Eriksson B Med Oncol; 2002; 19(1):35-42. PubMed ID: 12025889 [TBL] [Abstract][Full Text] [Related]
15. Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma). Bourcier ME; Vinik AI Pancreas; 2013 Mar; 42(2):348-52. PubMed ID: 23407483 [TBL] [Abstract][Full Text] [Related]
16. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Kraenzlin ME; Ch'ng JL; Wood SM; Carr DH; Bloom SR Gastroenterology; 1985 Jan; 88(1 Pt 1):185-7. PubMed ID: 2856877 [TBL] [Abstract][Full Text] [Related]
17. [Successful therapy of VIPoma with the long-acting somatostatin analogue SMS 201-995]. Maeda M; Niitsu Y; Goto Y; Kogawa K; Watanabe N; Kohgo Y; Urushizaki I Nihon Naika Gakkai Zasshi; 1988 Jan; 77(1):86-90. PubMed ID: 2897419 [No Abstract] [Full Text] [Related]
18. Somatostatin analogue SMS 201-995 long term therapy for vipoma. Juby LD; Burke DA; Axon AT Postgrad Med J; 1987 Apr; 63(738):287-9. PubMed ID: 2891127 [TBL] [Abstract][Full Text] [Related]
19. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Faiss S; Räth U; Mansmann U; Caird D; Clemens N; Riecken EO; Wiedenmann B Digestion; 1999; 60(5):469-76. PubMed ID: 10473972 [TBL] [Abstract][Full Text] [Related]
20. Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma. Damgé C; Hajri A Eur J Pharmacol; 1998 Apr; 347(1):77-86. PubMed ID: 9650851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]